Shenzhen, China- 30 January 2024 – MGI Tech Co., Ltd. (referred to as MGI), a leading provider of cutting-edge tools and technology for life science and healthcare research, today announced a strategic expansion of its automation product lines. This expansion covers sample pre-treatment, sample preparation and integrated testing, leveraging its innovative technologies and expertise in genetic sequencing and multi-omics.
MGI’s automation product lines aim to address the growing demand for high-throughput, efficient and reliable solutions in precision medicine, precision agriculture, precision healthcare and related industries.
Sample Pre-treatment:
MGI’s sample pre-treatment products extend from its successful COVID testing portfolio and include the High-throughput Automated Sample Transfer Processing System MGISTP-7000 and the Automated Sample Transfer Processing System MGISTP-3000. These solutions now cover a broader spectrum of samples and assays, including sample collection and extraction. The focus is on enabling fast and accurate DNA/RNA extraction, a pivotal step for downstream analysis.
Sample Preparation:
MGI’s sample preparation products offer a diverse range of systems for nucleic acid library construction. Highlights include the High-throughput Automated Sample Preparation System MGISP-960, the Automated Sample Preparation System MGISP-100, and the upgraded MGISP-Smart 8 system, featuring ProcessGo software for improved integration and user-friendly operation. The revolutionary automated lab-on-a-chip system, DNBeLab-D4, leverages advanced microfluidics technology to deliver unparalleled precision in digital PCR applications, setting a new standard for accuracy and efficiency in nucleic acid quantification. Additionally, the MGI-Glab system, a fully automated solution for large-scale projects, can handle up to thousands of samples per day, providing tailored solutions for clinical laboratories, research institutes and biotechnology companies.
Integrated Testing:
MGI’s integrated testing system feature the MGIFLP-L50 system, a modular sequencing workstation integrating the entire sequencing workflow into one machine. This fully automated solution supports diverse research and applications in microbiology, reproductive health and more.
MGI’s expansion of its automation product lines underscores its commitment to intelligent innovation in the life sciences, delivering advanced tools that enhance efficiency, accuracy and research turnaround times. Its comprehensive workflow solutions eliminate bottlenecks, enabling researchers to focus on data analysis rather than labour-intensive tasks.
“MGI is proud to announce the expansion of our automation product lines, providing advanced solutions to our life science and healthcare partners. Our vision centres on increased automation and intelligent features, empowering researchers to make data-driven decisions and contribute to societal advancement through continuous innovation,” said Duncan Yu, President of MGI.
MGI will showcase its complete portfolio of laboratory automation solutions at SLAS2024 and Medlab Middle East 2024. Attendees are invited to visit MGI’s subsidiary, Complete Genomics, at booth #1337 at SLAS2024 in Boston, 3–7 February 2024, and booth #Z4.H10 at Medlab Middle East 2024 in Dubai, 5–8 February 2024.
